Ikeda Yoko, Mori Kazuhiko, Tada Kaori, Ueno Morio, Kinoshita Shigeru, Sotozono Chie
Department of Ophthalmology, Kyoto Prefectural University of Medicine; Oike-Ganka Ikeda Clinic.
Department of Ophthalmology, Kyoto Prefectural University of Medicine.
Clin Ophthalmol. 2016 Aug 24;10:1633-7. doi: 10.2147/OPTH.S108213. eCollection 2016.
To evaluate and compare the intraocular pressure (IOP) reduction efficacy and safety between the ophthalmic solutions 0.005% latanoprost (Lat) and 0.0015% tafluprost (Taf) in Japanese patients with normal-tension glaucoma (NTG).
In this randomized nonmasked study, we prospectively enrolled 30 Japanese NTG patients who had used Lat monotherapy for more than 4 weeks, and randomly divided them into the following two groups: 1) Lat-to-Taf group (LT group) and 2) Taf-to-Lat group (TL group). At the beginning of the study, both groups were switched from initial Lat to Lat or Taf for 12 weeks, and then switched over to the other drug (crossover) for 12 additional weeks. At 0, 4, 12, 16, and 24 weeks, we evaluated each patient's IOP, conjunctival injection, and corneal epitheliopathy score, and at 0, 12, and 24 weeks, we evaluated their eyelash changes and pigmentation of the eyelids and irises.
The mean IOP of the LT group (15 eyes) was 10.5, 10.6, and 11.1 mmHg, at 0, 12, and 24 weeks, respectively, whereas that of the TL group (15 eyes) was 11.7, 11.1, and 10.5 mmHg at 0, 12, and 24 weeks, respectively. No significant differences were found between the two groups and in the intragroup comparisons. Moreover, no significant differences were found between Lat and Taf in regard to the conjunctival injection score and corneal epitheliopathy score. Eyelash changes and eyelid and iris pigmentation were similar in both groups.
The findings of this study show that Lat and Taf have equivalent efficacy and safety in Japanese patients with NTG.
评估并比较0.005%拉坦前列素（Lat）眼药水和0.0015%他氟前列素（Taf）眼药水对日本正常眼压性青光眼（NTG）患者降低眼压的疗效及安全性。
在这项随机非盲研究中，我们前瞻性纳入了30例使用Lat单药治疗超过4周的日本NTG患者，并将他们随机分为以下两组：1）Lat换Taf组（LT组）和2）Taf换Lat组（TL组）。研究开始时，两组均从初始的Lat转换为Lat或Taf治疗12周，然后再转换为另一种药物（交叉）治疗12周。在第0、4、12、16和24周，我们评估了每位患者的眼压、结膜充血和角膜上皮病变评分，在第0、12和24周，我们评估了他们的睫毛变化以及眼睑和虹膜色素沉着情况。
LT组（15只眼）在第0、12和24周时的平均眼压分别为10.5、10.6和11.1 mmHg，而TL组（15只眼）在第0、12和24周时的平均眼压分别为11.7、11.1和10.5 mmHg。两组之间以及组内比较均未发现显著差异。此外，Lat和Taf在结膜充血评分和角膜上皮病变评分方面也未发现显著差异。两组的睫毛变化以及眼睑和虹膜色素沉着情况相似。
本研究结果表明，Lat和Taf对日本NTG患者具有等效的疗效和安全性。
